(Reuters) -Legend Biotech said on Thursday it would set up a new research and development facility in Philadelphia, Pennsylvania, to advance its portfolio of next-generation cell therapies.
The company is studying its experimental cell therapies, which are in early-stage development, to treat different types of cancers.
The 31,000-square-foot facility is expected to be completed in the third quarter of 2025 and the expansion would build on the company’s existing research and development footprint in the United States, including a plant in Piscataway, New Jersey.
Legend, which has more than 1,200 employees in the U.S., expects 55 full-time employees would eventually be based in the new facility.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
Comments